Strumento inattivo

Altre lingue Circadian Technologies Limited Australian S.E.

Azioni

Prezzo di chiusura Australian S.E. Altri mercati azionari
- ^AUD	-

28/05	Opthea Limited completa l'arruolamento nel programma clinico pivotale di Fase 3 con Sozinibercept nella AMD umida	CI
28/05	Opthea completa gli arruolamenti negli studi COAST e ShORe	MT

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD	28/05
Opthea Completes Enrollments in COAST, ShORe Trials	28/05
Opthea Limited Announces Board Changes	03/04
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	29/02
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Opthea Appoints Chief Medical Advisor; Shares Decline 4%	20/02
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor	20/02
Opthea Concludes Enrollment in Inaugural Wet AMD Drug Trial	15/02
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept	14/02
Opthea Makes Management Appointments As Part of Next Stage Drug Trial; Shares Up 13%	02/02
Opthea Strengthens Team with Key Clinical and Regulatory Hires	01/02
Opthea to Receive Remaining Committed Funds, Additional Financing for Sozinibercept Trials; Shares Up Pre-Bell	27/12
Traders Look Ahead to Flat Day After Post-Christmas Rally	27/12
Top Premarket Gainers	27/12
Opthea Secures $85 Million for Advancing Clinical Trials, Pre-Commercialization Activities	27/12
Opthea Receives AU$9 Million Tax Rebate for Fiscal Year 2023	20/12
Opthea Limited Announces Transition of Megan Baldwin to Founder and Chief Innovation Officer, Effective October 27, 2023	27/10/23
Opthea Limited Announces Executive Changes	27/10/23
Opthea Completes Retail Entitlement Offer; Shares Fall 3%	21/09/23
Opthea's Options Suspended from Quotation on ASX; Shares Rise 3%	15/09/23

Non ci sono risultati per questa ricerca